I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock ExchangePRNewsWire • 07/27/21
ABL Bio Announces Publication of Preclinical Data Demonstrating Safety and Efficacy of ABL503/TJ-L14B, a Novel Anti-PD-L1 X 4-1BB Bispecific AntibodyPRNewsWire • 07/09/21
I-Mab Expands Emerging Portfolio of Next Generation Novel Oncology Therapeutics Through Cutting-Edge mRNA and AI Technology PlatformsPRNewsWire • 07/09/21
I-Mab Announces China NMPA Approval for Phase 1b Trial of Felzartamab in Systemic Lupus ErythematosusPRNewsWire • 06/25/21
I-Mab Appoints International Gastrointestinal Oncology Expert Dr. Andrew Zhu to its Scientific Advisory BoardPRNewsWire • 06/21/21
I-Mab to Hold Investor Call to Present In-Depth Phase 1 Clinical Data on Highly Differentiated CD73 Antibody UliledlimabPRNewsWire • 06/02/21
I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer SettingsBenzinga • 05/20/21
I-Mab Presents Phase 1 Data on Highly Differentiated CD73 Antibody Uliledlimab at ASCO 2021PRNewsWire • 05/19/21
I-Mab Announces First Patient Dosed in China Phase 2 Combination Trial of Lemzoparlimab with Azacitidine in Patients with Acute Myeloid Leukemia or Myelodysplastic SyndromePRNewsWire • 05/18/21
Week In Review: CANbridge Licenses LogicBio's Adeno-Associated Virus For Gene Therapies In $591 Million DealSeeking Alpha • 05/03/21
I-Mab's IL-6 Drug Hits Primary Endpoint Goal In Mid-Stage Ulcerative Colitis StudyBenzinga • 04/26/21
I-Mab Announces Positive Topline Phase 2 Results for Olamkicept in Ulcerative ColitisPRNewsWire • 04/26/21
I-Mab Announces Selected Poster Presentation of CD73 Antibody Uliledlimab at American Society of Clinical Oncology (ASCO) 2021 Annual MeetingGlobeNewsWire • 04/14/21
I-Mab and ABL Bio Receive US FDA Approval to Initiate Phase 1 Trial of Bispecific Antibody TJ-CD4B/ABL111 in Patients with Advanced or Metastatic Solid TumorsGlobeNewsWire • 03/30/21